Plain-English translation of NCT06801236 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called ACE-232 to see if it can help people with advanced prostate cancer that no longer responds to standard treatments. Researchers will study whether the medication is safe, how your body processes it, and whether it works against your cancer. The trial is divided into two stages: first, doctors will test different doses to find the safest level, and then they'll test the best dose in patients whose cancer has specific genetic changes.
Many people with advanced prostate cancer eventually develop resistance to hormone therapy and chemotherapy, leaving them with limited options. This trial is exploring whether this medication could offer a new treatment path for patients who have exhausted standard care.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic regularly to receive the medication and have blood work and scans to monitor your safety and how well the treatment is working. The trial has two parts: in the first part, the dose will gradually increase to find the safest level; in the second part, patients with specific cancer-related genetic changes will receive one of two selected doses. Throughout the study, your doctors will watch closely for any side effects and measure how your cancer responds to the treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States